We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Excessive pricing in pharmaceutical products attracts the European Commission’s attention

23 May 2017

Focus on Regulation

In recent years competition authorities in a number of EU Member States have stepped up in their pursuit against companies active in the Life Sciences sector for excessive pricing. Last week, the European Commission issued a press release signalling that it will not be left behind on the action when it launched a probe into a pharmaceutical supplier of cancer drugs. This could be one of the very first examples of intervention at the European Commission level in a pure excessive pricing case, let alone in the Life Sciences sector.

To read more, click here.


Loading data